194 related articles for article (PubMed ID: 31513929)
1. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles.
Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S
Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929
[TBL] [Abstract][Full Text] [Related]
2. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
[TBL] [Abstract][Full Text] [Related]
3. Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.
Fabre B; Ramos A; de Pascual-Teresa B
J Med Chem; 2014 Dec; 57(24):10205-19. PubMed ID: 25265401
[TBL] [Abstract][Full Text] [Related]
4. Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
Baidya SK; Banerjee S; Adhikari N; Jha T
J Med Chem; 2022 Aug; 65(16):10709-10754. PubMed ID: 35969157
[TBL] [Abstract][Full Text] [Related]
5. Specificity of binding with matrix metalloproteinases.
Gupta SP; Patil VM
Exp Suppl; 2012; 103():35-56. PubMed ID: 22642189
[TBL] [Abstract][Full Text] [Related]
6. Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1' cavity.
Devel L; Czarny B; Beau F; Georgiadis D; Stura E; Dive V
Biochimie; 2010 Nov; 92(11):1501-8. PubMed ID: 20696203
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors.
Lovejoy B; Welch AR; Carr S; Luong C; Broka C; Hendricks RT; Campbell JA; Walker KA; Martin R; Van Wart H; Browner MF
Nat Struct Biol; 1999 Mar; 6(3):217-21. PubMed ID: 10074939
[TBL] [Abstract][Full Text] [Related]
8. Role of sulfonamide group in matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Xu WF
Curr Med Chem; 2008; 15(4):368-73. PubMed ID: 18288991
[TBL] [Abstract][Full Text] [Related]
9. Selectivity, binding affinity, and ionization state of matrix metalloproteinase inhibitors.
Zhong HA; Arbiser J; Bowen JP
Curr Pharm Des; 2013; 19(26):4701-13. PubMed ID: 23260023
[TBL] [Abstract][Full Text] [Related]
10. Molecular Dynamics Simulations of Matrix Metalloproteinase 13 and the Analysis of the Specificity Loop and the S1'-Site.
Choi JY; Chung E
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445757
[TBL] [Abstract][Full Text] [Related]
11. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach.
Terp GE; Cruciani G; Christensen IT; Jørgensen FS
J Med Chem; 2002 Jun; 45(13):2675-84. PubMed ID: 12061871
[TBL] [Abstract][Full Text] [Related]
12. Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview.
Adhikari N; Mukherjee A; Saha A; Jha T
Eur J Med Chem; 2017 Mar; 129():72-109. PubMed ID: 28219048
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation.
Fischer T; Riedl R
Molecules; 2019 Jun; 24(12):. PubMed ID: 31216704
[TBL] [Abstract][Full Text] [Related]
14. Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.
Sawa M; Kondo H; Nishimura S
Bioorg Med Chem Lett; 2002 Feb; 12(4):581-4. PubMed ID: 11844676
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
16. Structure analysis reveals the flexibility of the ADAMTS-5 active site.
Shieh HS; Tomasselli AG; Mathis KJ; Schnute ME; Woodard SS; Caspers N; Williams JM; Kiefer JR; Munie G; Wittwer A; Malfait AM; Tortorella MD
Protein Sci; 2011 Apr; 20(4):735-44. PubMed ID: 21370305
[TBL] [Abstract][Full Text] [Related]
17. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors.
Laghezza A; Luisi G; Caradonna A; Di Pizio A; Piemontese L; Loiodice F; Agamennone M; Tortorella P
Bioorg Med Chem; 2020 Feb; 28(3):115257. PubMed ID: 31874775
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics simulations of metalloproteinases types 2 and 3 reveal differences in the dynamic behavior of the S1' binding pocket.
de Oliveira CA; Zissen M; Mongon J; McCammon JA
Curr Pharm Des; 2007; 13(34):3471-5. PubMed ID: 18220784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
